Next Article in Journal
Immune Resistance and EGFR Antagonists in Colorectal Cancer
Previous Article in Journal
New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma
Review

Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox

1
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
2
Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
3
Early Clinical Trials Development, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD 20892, USA
*
Authors to whom correspondence should be addressed.
Cancers 2019, 11(8), 1087; https://doi.org/10.3390/cancers11081087
Received: 13 June 2019 / Revised: 11 July 2019 / Accepted: 17 July 2019 / Published: 31 July 2019
Evasion from apoptosis is an important hallmark of cancer cells. Alterations of apoptosis pathways are especially critical as they confer resistance to conventional anti-cancer therapeutics, e.g., chemotherapy, radiotherapy, and targeted therapeutics. Thus, successful induction of apoptosis using novel therapeutics may be a key strategy for preventing recurrence and metastasis. Inhibitors of anti-apoptotic molecules and enhancers of pro-apoptotic molecules are being actively developed for hematologic malignancies and solid tumors in particular over the last decade. However, due to the complicated apoptosis process caused by a multifaceted connection with cross-talk pathways, protein–protein interaction, and diverse resistance mechanisms, drug development within the category has been extremely challenging. Careful design and development of clinical trials incorporating predictive biomarkers along with novel apoptosis-inducing agents based on rational combination strategies are needed to ensure the successful development of these molecules. Here, we review the landscape of currently available direct apoptosis-targeting agents in clinical development for cancer treatment and update the related biomarker advancement to detect and validate the efficacy of apoptosis-targeted therapies, along with strategies to combine them with other agents. View Full-Text
Keywords: apoptosis; cancer; intrinsic apoptosis; extrinsic apoptosis; biomarker; targeted therapy apoptosis; cancer; intrinsic apoptosis; extrinsic apoptosis; biomarker; targeted therapy
Show Figures

Figure 1

MDPI and ACS Style

Lim, B.; Greer, Y.; Lipkowitz, S.; Takebe, N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers 2019, 11, 1087. https://doi.org/10.3390/cancers11081087

AMA Style

Lim B, Greer Y, Lipkowitz S, Takebe N. Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox. Cancers. 2019; 11(8):1087. https://doi.org/10.3390/cancers11081087

Chicago/Turabian Style

Lim, Bora, Yoshimi Greer, Stanley Lipkowitz, and Naoko Takebe. 2019. "Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox" Cancers 11, no. 8: 1087. https://doi.org/10.3390/cancers11081087

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop